This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Hang on a second…

This CME Activity has expired and is no longer available for credit.

Best of the 16th Annual South Beach Symposium: Virtual Highlights on Atopic Dermatitis, Psoriasis, and Aesthetics

Best of the 16th Annual South Beach Symposium: Virtual Highlights on Atopic Dermatitis, Psoriasis, and Aesthetics



Time to Complete

1 hour


April 19, 2018


April 19, 2019
Add to Queue

Maximum Credits

1.00 / AMA PRA Category 1 CreditTM
1.00 / CNE Contact Hour

Accredited Provider

Provided by Global Medical Education

Commercial Supporter

This activity is supported by educational grants from Allergan, Celgene Corporation, Fougera Pharmaceuticals, Inc., Lilly USA, LLC, and Pfizer.

Program Description

The South Beach Symposium (SBS) 2018 Highlights features three talks related to therapeutic advances in psoriasis, recent developments in the treatment of atopic dermatitis, and combination techniques in aesthetics. This one-hour online video is taught by SBS faculty members Mark Lebwohl, MD, Leon Kircik, MD, and Susan Weinkle, MD.

Intended Audience

The educational design of this activity addresses the needs of physicians, nurses, and professional staff members of medical practices involved in the treatment of patients in dermatology, pediatric dermatology, plastic surgery, cosmetic surgery, and other dermatologic medical procedures.

Educational Objectives

Upon completion of the activity, participants should be better able to:

  • Evaluate treatment strategies for moderate-to-severe psoriasis based on an understanding of psoriasis as a systemic immune-mediated disease
  • Discuss individualized treatment plans for pediatric and adult patients with moderate-to-severe AD based on current guideline recommendations for AD, the safety and efficacy of new and emerging treatment options, comorbidities, and patient quality of life
  • Compare the efficacy and safety of agents, and techniques currently available in aesthetic dermatology
  • List the appropriate filler agent to target specific patient characteristics to treat different areas of the face and targeted planar depths

Conflict Of Interest Disclosure Policy

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.


Mark G. Lebwohl, MD
Waldman Professor and Chairman
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine
Mount Sinai Medical Center
New York, NY

Dr. Lebwohl discloses the following:
Research/Grant Support: Abbvie, Boehringer Ingelheim, Celgene, Eli Lilly, Incyte, Janssen/Johnson & Johnson, Leo Pharmaceuticals, Medimmune/Astra Zeneca, Novartis, Pfizer, Sciderm, Valeant, ViDac
Consultant: Allergan, Aqua, Dr. Reddy's Laboratorie

Leon Kircik, MD
Associate Clinical Professor of Dermatology
Indiana University Medical Center in Indianapolis, IN
Icahn School of Medicine
Mount Sinai Medical Center
New York, NY

Dr. Kircik discloses the following:
Speaker/Honoraria: Abbott Laboratories, Allergan, Amgen, Assos Pharma, Astellas Pharma, Cipher, CollaGenex, Connetics Corporation, Dermik Laboratories, Embil Pharmaceuticals, Exeltis, Galderma, Genentech, Innocutis, Innovail, Johnson & Johnson, Leo, L'Oreal, 3M, Onset, OrthoNeutrogena, PediaPharma, PharmaDerm, Serono (Merck Serono International SA), SkinMedica, Inc, Stiefel Laboratories, Inc, Sun Pharma, Taro, Triax, UCB, Valeant Pharmaceuticals Intl, Warner-Chilcott
Consultant: Allergan, Almirall, Amgen, Anacor Pharmaceuticals, Colba, Cipher, CollaGenex, Connetics Corporation, Exeltis, Galderma, Genentech, Intendis, Isdin, Johnson & Johnson, Laboratory Skin Care Inc, Leo, Medical International Technologies, Merck, Merz, OrthoNeutrogena, Promius, PuraCap, SkinMedica, Inc, Stiefel Laboratories, Inc, Sun Pharma, Taro, UCB, Valeant Pharmaceuticals Intl, ZAGE
Advisory Board: Aclaris, Allergan, Almirall, Anacor Pharmaceuticals, Biogen-Idec, Colba, Celgene, Cipher, EOS, Exeltis, Ferndale Laboratories, Galderma, Genentech, Intendis, Innocutis, Isdinm, Johnson & Johnson, Nano Bio, OrthoNeutrogena, Promius, Quinnova, SkinMedica, Inc, Stiefel Laboratories, Inc, Sun Pharma, Valeant Pharmaceuticals Intl, Warner-Chilcott
Investigator: Acambis, Allergan, Amgen, Anacor Pharmaceuticals, Astellas Pharma, Asubio, Berlex, Laboratories (Bayer HealthCare Pharmaceuticals), Biolife, Biopelle, Boehringer-Ingleheim, Breckinridge Pharma, Celgene, Centocor, Inc, Cellceutix, Coherus, CollaGenex, Combinatrix, Connetics Corporation, Coria, Dermavant, Dermira, Dow Pharmacutical Sciences, Inc., Dusa, Eli Lilly, Exeltis, Ferndale Laboratories, Galderma, Genentech, GlaxoSmithKline, Health Point LTD, Idera, Intendis, Johnson & Johnson, Leo, L'Oreal, 3M, maruho, Merck, Medicis Pharmaceutical Corp, Nano Bio, Noven Pharmaceuticals, Nucryst Pharmaceuticals Corp, Obagi, Onset, OrthoNeutrogena, Promius, QLT, Inc., PharmaDerm, Pfizer, Quinnova, Quatrix, SkinMedica, Inc, Stiefel Laboratories, Inc, Sun Pharma, TolerRx, UCB, Valeant Pharmaceuticals Intl, Warner-Chilcott, XenoPort
Stockholder: Johnson & Johnson

Susan H. Weinkle, MD
Cosmetic Dermatology/ Mohs Surgery
Affiliate Clinical Professor
University of South Florida
Bradenton, FL

Dr. Weinkle discloses the following:
Consultant: Allergan/Galderma
Grant/Research Support: Revance, Alphaeon, Teoxane
Honoraria: Revance/Sinclair
Speaker’s Bureau: Sinclair
Stock Shareholder: Dermvance

Accredited Provider Disclosure

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN, has nothing to disclose
Lindsay Borvansky has nothing to disclose
Andrea Funk has nothing to disclose
Liddy Knight has nothing to disclose

Publishing Staff Disclosures

Tiffany Robbins has nothing to disclose
Vivian Grifantini has nothing to disclose




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and The South Beach Symposium. Global is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Global Education Group designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 CreditTM .   Physicians should claim only the credit commensurate with the extent of their participation in the activity.




CNE Contact Hour(s)

Accreditation Statement

Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Designation Statement

This educational activity for 1.00 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and the South Beach Symposium do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities


To obtain credit, a score of 75% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact: Global at 303-395-1782 or

Privacy Policy


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue